^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Akynzeo oral (netupitant/palonesteron FDC)

    i
    Other names: NEPA
    Associations

    News

    Trials
    Company:
    Fosun Pharma, Glenmark, Helsinn, Immedica, Knight Therap, Mundipharma, Otsuka, Roche
    Drug class:
    NK-1 antagonist, Serotonin 3 receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    9ms
    A Retrospective Study on the Efficacy and Safety of Oral NEPA Capsules in Preventing Nausea and Vomiting in Nasopharyngeal Carcinoma Patients after Cisplatin Chemotherapy (ChiCTR2500097314)
    P=N/A, N=246, Completed, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University
    New trial
    |
    cisplatin • Akynzeo oral (netupitant/palonesteron FDC)
    10ms
    A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 Mg and Metabolites in Healthy Volunteers (clinicaltrials.gov)
    P1, N=50, Terminated, Helsinn Healthcare SA
    New P1 trial
    |
    Akynzeo oral (netupitant/palonesteron FDC) • netupitant (Ro 67-3189)
    1year
    AKY15-HK-301_NEPA Study (clinicaltrials.gov)
    P2, N=55, Active, not recruiting, Chinese University of Hong Kong | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    doxorubicin hydrochloride • cyclophosphamide • dexamethasone • Akynzeo oral (netupitant/palonesteron FDC)
    1year
    NOEME: Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer (clinicaltrials.gov)
    P4, N=84, Recruiting, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    New P4 trial
    |
    Akynzeo oral (netupitant/palonesteron FDC)
    1year
    Oral Akynzeo® Vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) (clinicaltrials.gov)
    P4, N=414, Completed, Helsinn Healthcare SA | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024
    Trial completion • Trial completion date
    |
    Akynzeo oral (netupitant/palonesteron FDC) • granisetron oral • ondansetron intravenous
    1year
    Exploratory study on a single-day low-dose dexamethasone combined with a single or double standard dose of netupitant palonosetron capsules for preventing nausea and vomiting in patients undergoing moderately to highly emetogenic chemotherapy (LD-NEPA1/2 study) (ChiCTR2400089311)
    P=N/A, N=164, Not yet recruiting, Zhongshan Hospital Affiliated to Xiamen University; Zhongshan Hospital Affiliated to Xiamen University
    New trial
    |
    Akynzeo oral (netupitant/palonesteron FDC) • dexamethasone injection
    over1year
    Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer (clinicaltrials.gov)
    P3, N=1351, Completed, University of Rochester NCORP Research Base | Recruiting --> Completed | Trial completion date: Jun 2024 --> Feb 2024
    Trial completion • Trial completion date
    |
    Akynzeo oral (netupitant/palonesteron FDC) • olanzapine
    over1year
    Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) (clinicaltrials.gov)
    P4, N=414, Active, not recruiting, Helsinn Healthcare SA | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2024 --> Jul 2024
    Enrollment closed • Trial primary completion date
    |
    Akynzeo oral (netupitant/palonesteron FDC) • granisetron oral • ondansetron intravenous
    over1year
    NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens (clinicaltrials.gov)
    P3, N=627, Not yet recruiting, Fudan University
    New P3 trial • Head-to-Head
    |
    dexamethasone • Akynzeo oral (netupitant/palonesteron FDC) • olanzapine
    almost2years
    Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer (clinicaltrials.gov)
    P3, N=1600, Recruiting, University of Rochester NCORP Research Base | Trial completion date: Jun 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Apr 2024
    Trial completion date • Trial primary completion date
    |
    Akynzeo oral (netupitant/palonesteron FDC) • olanzapine
    2years
    AKY15-HK-301_NEPA Study (clinicaltrials.gov)
    P2, N=55, Active, not recruiting, Chinese University of Hong Kong | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    doxorubicin hydrochloride • cyclophosphamide • dexamethasone • Akynzeo oral (netupitant/palonesteron FDC)
    5years
    A three-arm study comparing a standard regimen of dexamethasone with two dex-sparing regimens in addition to NEPA in preventing chemotherapy-induced nausea and vomiting (CINV) in na¿ve non-small cell lung cancer (NSCLC) patients to be treated with cisplatin based chemotherapy Studio a tre bracci di trattamento che confronta un regime standard e due regimi ridotti di desametasone, in associazione a NEPA, per la prevenzione della nausea e del vomito indotti da chemioterapia (CINV) in pazienti na¿ve con tumore del polmone non a piccole cellule (NSCLC) in trattamento con chemioterapia a base di cisplatino (clinicaltrialsregister.eu)
    P3, N=219, Completed, CONSORZIO ONCOTECH
    Clinical • New P3 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    cisplatin • Akynzeo oral (netupitant/palonesteron FDC)